Management of Chronic Hepatitis B with Nucleoside or Nucleotide Analogues: A Review of Current Guidelines
Open Access
- 30 March 2010
- journal article
- review article
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 4 (1), 15-24
- https://doi.org/10.5009/gnl.2010.4.1.15
Abstract
Antiviral treatment of hepatitis B is one of the most rapidly evolving fields in current medicine. Guidelines for the management of chronic hepatitis B (CH-B) have been proposed and revised by many academic societies and groups. Recommendations for nucleoside or nucleotide analogue (NUC) therapy from representative current guidelines are compared herein with each other and with previous guidelines. Several differences among individual recommendations may reflect regional and temporal differences as well as differences in the available data upon which the guidelines are based. Nevertheless, these guidelines share a common principle regarding NUC treatment for CH-B: long-term viral suppression by the drugs with potent antiviral activity and low rate of development of drug resistance to prevent disease progression. A review of the past and current guidelines for the management of CH-B would be useful for evaluating the current status of management of the disease and to identify better solutions for improving the outcome of patients with CH-B.Keywords
This publication has 33 references indexed in Scilit:
- Chronic hepatitis B: Update 2009Hepatology, 2009
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapyHepatology, 2009
- Liver biopsyHepatology, 2008
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 updateHepatology International, 2008
- Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B PatientsGastroenterology, 2007
- The clinical significance of persistently normal ALT in chronic hepatitis B infectionJournal of Hepatology, 2007
- Management of Chronic Hepatitis BThe Korean Journal of Hepatology, 2007
- Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral LoadGastroenterology, 2006
- Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationJournal of Hepatology, 2005
- Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infectionHepatology, 2002